Effect of Tolvaptan in Patients with Chronic Kidney Disease Stage G5 and Impact of Concomitant Use of Thiazide Diuretics: A Retrospective Cohort Study

Drugs – Real World Outcomes

Kiyotaka Uchiyama¹, Daiki Kojima¹, Eriko Yoshida Hama¹, Tomoki Nagasaka¹, Takashin Nakayama¹, Rina Takahashi¹, Takaya Tajima¹, Kohkichi Morimoto², Naoki Washida¹,³, Hiroshi Itoh¹

¹Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan
²Apheresis and Dialysis Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, Japan
³Department of Nephrology, International University of Health and Welfare School of Medicine, 4-3, Kozunomori, Narita, Chiba, Japan

Corresponding Author:

Kiyotaka Uchiyama, MD, PhD
Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Tel: +81-3-5363-3796
Fax: +81-3-3359-2745
E-mail: kiyo.0817.piyo@gmail.com
Table S1. Multivariate linear regression analysis to determine variables associated with post-24-h urinary volume with adjustment for the change in loop diuretic dose

| Variables                  | Post-urinary volume (mL/day)\(^a\) | Post-urinary volume (mL/day)\(^a,b\) (n = 67) |
|----------------------------|-------------------------------------|---------------------------------------------|
|                            | \(\beta\)-coefficient \(95\%\) CI  | \(P\)                               | \(\beta\)-coefficient \(95\%\) CI  | \(P\)                  |
| Thiazide diuretics         | −503.6                              | −675.8 to −331.4 | <0.001                      | −449.5                              | −616.5 to −282.5 | <0.001 |
| eGFR (mL/min/1.73 m\(^2\)) | 21.0                                | −4.4 to 46.4      | 0.10                        | 6.5                                | −18.6 to 31.5    | 0.61   |
| Albumin (g/dL)             | 1.14                                | −147.0 to 149.3   | 0.99                        | −25.0                              | −167.4 to 117.3 | 0.73   |
| BNP (pg/mL)                | 0.057                               | −0.029 to 0.14    | 0.19                        | 0.034                              | −0.046 to 0.11  | 0.40   |
| UPCR (g/gCre)              | 0.95                                | −15.34 to 17.24   | 0.44                        | 0.85                               | −14.85 to 16.54 | 0.91   |

Change in loop diuretic doses

|                          |                                |                                |
|--------------------------|--------------------------------|--------------------------------|
| Decreased vs. remained   | 182.6                         | −8.8 to 374.0                  | 0.06                      | —                                | —                 |
| Decreased vs. increased  | 563.9                         | 321.9 to 806.0                 | <0.001                    | —                                | —                 |

\(^a\) Adjusted for preurinary volume

\(^b\) Including only the patients in whom the dose of loop diuretics remained unchanged

BNP, brain natriuretic peptide; CI, confidence interval; eGFR, estimated glomerular filtration rate; and UPCR, urinary protein-to-creatinine ratio.